Matrix Metalloproteinase 9
Research News and Information

Monday, November 23, 2009

Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.

13 Nov 2009 Death receptors of the tumor necrosis factor (TNF) receptor super family have been implicated in constitutive activation of nuclear factor-kappa B (NF-kappaB) in pancreatic cancer (PaC) cells. In this study, we demonstrate that fisetin, a natural ... Read more...

Involvement of cytosolic phospholipase A2alpha in MMP-9 up-regulation.

30 Oct 2009 Matrix metalloproteinase-9 (MMP-9) is important in the pathogenesis of periodontitis. Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) is involved in MMP-9 up-regulation in human monocytes. We tested the hypothesis that cPLA(2)alpha also regulates ... Read more...

Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.

30 Oct 2009 Because of the poor prognosis and the development of resistance against chemotherapeutic drugs, the current treatment for advanced metastatic colorectal cancer (CRC) is ineffective. Whether curcumin (a component of turmeric) can potentiate the ... Read more...

Latest indexed articles for 'Matrix Metalloproteinase 9'

These are the very latest articles for this heading:

• Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. 13 Nov 2009
• Involvement of cytosolic phospholipase A2alpha in MMP-9 up-regulation. 30 Oct 2009
• Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. 30 Oct 2009
• Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. 30 Oct 2009
• CXCL14 inhibits trophoblast outgrowth via a paracrine/autocrine manner during early pregnancy in mice. 30 Oct 2009
• Salivary analysis of oral cancer biomarkers. 4 Oct 2009
• Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9. 3 Oct 2009
• Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. 29 Sep 2009
• Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. 29 Sep 2009
• Caveolin-1 tumor-promoting role in human melanoma. 29 Sep 2009
• DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin. 29 Sep 2009
• Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. 29 Sep 2009
• Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. 29 Sep 2009
• Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. 29 Sep 2009
• A novel approach to using matrix metalloproteinases for bladder cancer. 14 Sep 2009
• Editorial comment. 14 Sep 2009
• Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. 13 Sep 2009
• Significant changes in mitral valve leaflet matrix composition and turnover with tachycardia-induced cardiomyopathy. 13 Sep 2009
• Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. 13 Sep 2009
• Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. 7 Sep 2009

See a longer list of these articles.

Technical information about 'Matrix Metalloproteinase 9'

Definition: An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V.

Registry Number: EC 3.4.24.35

Descriptor UI: D020780

Alternative terms: Matrix Metalloproteinase 9; Metalloproteinase 9, Matrix; 92-kDa Type IV Collagenase; 92 kDa Type IV Collagenase; MMP9 Metalloproteinase; Metalloproteinase, MMP9; Matrix Metalloproteinase-9; MMP-9 Metalloproteinase; MMP 9 Metalloproteinase; Metalloproteinase, MMP-9; 92-kDa Gelatinase; 92 kDa Gelatinase; Gelatinase B;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.277.656.300.480.205.360; D08.811.277.656.300.480.252.445; D08.811.277.656.300.480.525.700.350; D08.811.277.656.675.374.205.360; D08.811.277.656.675.374.252.445; D08.811.277.656.675.374.525.700.350;

History Note: 2007(2000)